Search research articles
Contact Us
Filters
Showing results (1021-1030 of 1,197) with videos related to
Page
of 120
Sort By:
Hormones (Athens, Greece)
|
August 6, 2025
EndoBridge 2024: pearls and highlights
Bulent Okan Yildiz, Eleni Armeni, Chrysanthi Balodimou, et al.
Nature Genetics
|
June 26, 2012
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA
Marjorie J Lindhurst, Victoria E R Parker, Felicity Payne, et al.
Nucleic Acids Research
|
January 10, 2003
CDD: a curated Entrez database of conserved domain alignments
Aron Marchler-Bauer, John B Anderson, Carol DeWeese-Scott, et al.
Nucleic Acids Research
|
December 16, 2006
Database resources of the National Center for Biotechnology Information
David L Wheeler, Tanya Barrett, Dennis A Benson, et al.
NPJ Primary Care Respiratory Medicine
|
May 26, 2022
Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers
Janwillem W H Kocks, Hans Wouters, Sinthia Bosnic-Anticevich, et al.
Nucleic Acids Research
|
January 10, 2003
MMDB: Entrez's 3D-structure database
Jie Chen, John B Anderson, Carol DeWeese-Scott, et al.
Nucleic Acids Research
|
November 30, 2007
Database resources of the National Center for Biotechnology Information
David L Wheeler, Tanya Barrett, Dennis A Benson, et al.
The Lancet. Haematology
|
November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
Nucleic Acids Research
|
October 23, 2008
Database resources of the National Center for Biotechnology Information
Eric W Sayers, Tanya Barrett, Dennis A Benson, et al.
Trials
|
November 4, 2021
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, et al.
Page
of 120
Search research articles
Search
Showing results (1021-1030 of 1,197) with videos related to
Sort By:
Page
of 120
Hormones (Athens, Greece)
|
August 6, 2025
EndoBridge 2024: pearls and highlights
Bulent Okan Yildiz, Eleni Armeni, Chrysanthi Balodimou, et al.
Nature Genetics
|
June 26, 2012
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA
Marjorie J Lindhurst, Victoria E R Parker, Felicity Payne, et al.
Nucleic Acids Research
|
January 10, 2003
CDD: a curated Entrez database of conserved domain alignments
Aron Marchler-Bauer, John B Anderson, Carol DeWeese-Scott, et al.
Nucleic Acids Research
|
December 16, 2006
Database resources of the National Center for Biotechnology Information
David L Wheeler, Tanya Barrett, Dennis A Benson, et al.
NPJ Primary Care Respiratory Medicine
|
May 26, 2022
Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers
Janwillem W H Kocks, Hans Wouters, Sinthia Bosnic-Anticevich, et al.
Nucleic Acids Research
|
January 10, 2003
MMDB: Entrez's 3D-structure database
Jie Chen, John B Anderson, Carol DeWeese-Scott, et al.
Nucleic Acids Research
|
November 30, 2007
Database resources of the National Center for Biotechnology Information
David L Wheeler, Tanya Barrett, Dennis A Benson, et al.
The Lancet. Haematology
|
November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
Nucleic Acids Research
|
October 23, 2008
Database resources of the National Center for Biotechnology Information
Eric W Sayers, Tanya Barrett, Dennis A Benson, et al.
Trials
|
November 4, 2021
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, et al.
Page
of 120